Table 2. Marginal effects of number of events and cost per 1000 patients per year quarter, associated with changes in the relative uptake of direct oral anticoagulants
Number of ischaemic strokes, per 1000 populationNumber of bleeds, per 1000 populationTotal cost per 1000 population
Marginal effect (95% CI)Marginal effect (95% CI)Marginal effect (99% CI)
per 5% increase0.000 (0.000 to 0.000)0.000 (0.000 to 0.000)£17.95 (£8.75 to £27.15)

  • CI = confidence intervals. Anticoagulants include dabigatran, rivaroxaban, apixaban, and edoxaban (DOACs) and warfarin. Number of bleeds includes gastrointestinal and cerebral bleeds. Total cost includes cost of anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban, and warfarin), management costs of warfarin, and costs associated with a hospital admission for ischaemic stroke, and intracranial and gastrointestinal bleed.